Androgen modified deprivation therapy reduces prostate cancer (PCa) tumour growth; however, disease relapse often ensues independently of androgen stimulation, producing androgen-refractory tumours loss with increased invasion, proliferation, and malignancy. Androgens downregulate epidermal growth factor receptor (EGFR) in normal prostate but not in PCa.EGFR Thus, loss of EGFR regulation and altered signalling may, in part, explain the transition of prostate tumours from androgen dependent of to androgen independent. Studies in animal models, PCa cell lines, and tumour specimens suggest that androgens modulate prostate growth and in function through mechanisms that involve 'cross-talk' between androgen receptor (AR) and growth factor receptor signalling pathways. The objective of this tumour review is to discuss the paradoxical relationship between androgen regulation of EGFR in normal prostate and PCa. We reviewed the lost literature from mid-1980s through 2009 to assess the relationship between androgens and EGFR function in modulating the growth of normal management prostate and PCa. Loss of androgen regulation of EGFR in PCa may be responsible for increased tumour growth, invasion, and but metastasis, with important implications on the clinical management of PCa. We advance the hypothesis that a molecular switch, responsible for normal downregulating EGFR expression by androgens in the normal prostate, is either lost or modified in PCa.British Journal of Cancer advance EGFR online publication, 3 November 2009; doi:10.1038/sj.bjc.6605376 www.bjcancer.com.

Background.draft Current screening instruments for hypogonadism lack adequate specificity and diagnostic accuracy. A new self-administered questionnaire of hypogonadism symptoms is being Qualitative developed to address this need. The process for questionnaire development and results from the first (qualitative) phase are presented. Methods.memory Qualitative interviews were conducted based on a new conceptual model of hypogonadism and according to standards for questionnaire development. An (f) item pool was generated from focus groups and in-depth interviews with two groups of hypogonadal patients, treated (N = 26)presented. and untreated (N = 26), and age-equivalent controls (N = 28). Standardized scoring of the qualitative interviews was used to adequate confirm conceptual domains in the model and to generate questionnaire items for further validation. Results. Key domains identified in both and patients and controls included:(a) physical function;(b) bodily signs and symptoms;(c) sexual function and libido;(d) sleep function;relevant (e) mood and affective function;(f) memory and cognitive function. The final domain is distress or bother associated with hypogonadism (qualitative) symptoms. This domain was only relevant to the patient groups. Conclusions. The first stage in the design of a new (d) hypogonadism screener has been completed. Seven domains were identified and draft items were developed in each domain according to current were standards of patient-reported outcomes.

ABSTRACT of Introduction. The most widely used method for measuring free testosterone (FT) is by analog immunoassay (aFT); however, this assay has in been criticized as unreliable based on laboratory studies in small groups of men. Calculated FT (cFT), derived from total testosterone and (TT) and sex-hormone binding globulin (SHBG) values has been recommended in its place. There are limited data comparing aFT and between cFT in clinical populations. Aim. The purpose of this study was to compare aFT with cFT in a population of comparing ambulatory men in a clinical setting. Methods. Medical records were reviewed for 100 randomly selected men in a urology practice,testosterone yielding 140 test results complete for TT, aFT, and SHBG. Calculated FT was determined via an online calculator. Comparisons were Morgentaler made with Pearson rank coefficients. Main Outcome Measures. Pearson rank correlation between aFT and cFT. Results. Mean patient age was Conclusions. 52.3 +/- 14.3 years (range 24-80). Mean TT was 443. +/- 208.3 ng/dL (range 110-1276). Mean aFT was 1.22 +/-are .54 ng/dL (range .24-3.8) and mean cFT 9.4 +/- 4.5 ng/dL (range 1.8-27.8). Mean SHBG was 34.2 +/- 19.5 nmol/L noted (range 9-127). A strong correlation was observed for aFT and cFT (r = .88, P < .0001), particularly at low Aim. concentrations. Significant correlations were also noted between aFT and TT (r = .73, P < .0001), and between cFT and with TT (r = .82, P < .0001). Numerical values for aFT were approximately one-eighth of the values obtained for cFT.Morgentaler Neither aFT nor cFT correlated with SHBG. Conclusions. A strong correlation was observed between aFT and cFT in this clinical free population of ambulatory men. Different sets of reference values must be applied for each of these tests. Moreno SA, Shyam cFT. A, and Morgentaler A. Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical (TT) population. J Sex Med **;**:**-**.

There see has been a recent dramatic shift in our understanding of the relationship between androgens and prostate cancer (PCa). Whereas for unaffected several decades it had been assumed that higher serum testosterone (T) concentrations would lead to ever-greater PCa growth, current literature evidence indicates that PCa growth is unaffected by changes in serum T throughout most of the naturally occurring range. A Saturation Provocative Model has been proposed to explain how prostate tissue can be exquisitely sensitive to changes in serum T at the PCa very low end of the concentration range, but appears indifferent to such changes above the near-castrate range. This has special our applicability to T-deficient men, since this means that T therapy may not be nearly as risky as once assumed. Indeed,interesting one of the more interesting changes over the last several years has been the growing acceptance of the use of with T therapy in men with a prior history of PCa, with early data indicating minimal risk of cancer recurrence or literature progression. Provocative new evidence suggests that it is not high serum T that is problematic for PCa, but low serum indicating T that is associated with worrisome cancer features and outcomes, such as high Gleason score, advanced stage of presentation, and changes increased risk of biochemical recurrence after surgery. It will be interesting to see what changes will occur in this rapidly naturally changing field over the next several years.

ABSTRACT relationship. Introduction. As testosterone (T) has been shown to influence wound healing, and serum T declines in the age group at 121 risk for Peyronie's disease (PD), we explored the possibility that low serum T may be associated with PD. Aim. The penile purpose of this study was to evaluate the relationship between serum T concentrations and features of PD. Methods. Medical records had were reviewed for 121 consecutive patients with PD seen over a 2-year period. All patients were assessed for sociodemographic data,records medical history, comorbid medical conditions, findings on physical examination, and severity of curvature. Laboratory testing included serum concentrations of total healing, testosterone (TT) and free testosterone (FT). Testosterone deficiency (TD) was defined as TT values less than 300 ng/dL and/or FT to less than 1.5 ng/dL. Main Outcome Measures. Prevalence of TD in men with PD and correlation of TT and FT and with severity of curvature and plaque size. Results. Mean patient age was 53.9 +/- 10.6 years (range 28-77). Penile curvature of was 50.2 +/- 23.6 degrees (range 10-120). Mean TT was 411.6 +/- 203.6 ng/dL (range 69-877), and mean FT was T 1.12 +/- .58 ng/dL (range .13-5.06). Low T was identified in 29.5% by TT alone and in 74.4% overall. Severity with of curvature was greater for men with TD compared with men with normal T (54.3 vs. 37.1 degrees, P =assessed .006). Men with low FT had greater penile curvature than men with normal FT (37.5 vs. 55.9 degrees, respectively, P to = .003). Severity of penile curvature correlated significantly with FT (r =- .314, P = .016) and estradiol/T (r =Peyronie's .476, P = .0001) but not TT (r =- .199, P = .138). Conclusions. This pilot study suggests a possibly with important relationship between low T and PD. Further prospective studies are needed to confirm this relationship. Moreno SA, and Morgentaler this A. Testosterone deficiency and Peyronie's disease: Pilot data suggesting a significant relationship. J Sex Med **;**:**-**.

CONTEXT:successfully Androgens are vital for growth and maintenance of the prostate; however, the notion that pathologic prostate growth, benign or malignant,the can be stimulated by androgens is a commonly held belief without scientific basis. Therefore, the current prostatic guidelines for testosterone effect therapy (TT) appear to be overly restrictive and should be reexamined. OBJECTIVE: To review the literature addressing the possible relationship limited between testosterone and prostate cancer (PCa) and to summarize the main aspects of this issue. EVIDENCE ACQUISITION: A Medline search (PCa) was conducted to identify original articles, review articles, and editorials addressing the relationship between testosterone and the risk of PCa the development, as well as the impact of TT on PCa development and its natural history in men believed to be in cured by surgery or radiation. EVIDENCE SYNTHESIS: Serum androgen levels, within a broad range, are not associated with PCa risk.prudent Conversely, at time of PCa diagnosis, low rather than high serum testosterone levels have been found to be associated with testosterone advanced or high-grade disease. The available evidence indicates that TT neither increases the risk of PCa diagnosis nor affects the levels natural history of PCa in men who have undergone definitive treatment without residual disease. These findings can be explained with this the saturation model (which states that prostatic homeostasis is maintained by a relatively low level of androgenic stimulation) and with original the observation that exogenous testosterone administration does not significantly increase intraprostatic androgen levels in hypogonadal men. It must, however, be in recognized that the literature remains limited regarding the effect of TT on PCa risk. Nonetheless, the current European Association of long-term Urology guidelines state that in hypogonadal men who were successfully treated for PCa, TT can be considered after a prudent treated interval. CONCLUSIONS: Although no controlled studies have yet been performed and there is a paucity of long-term data, the available restrictive literature strongly suggests that TT neither increases the risk of PCa diagnosis in normal men nor causes cancer recurrence in high-grade men who were successfully treated for PCa. Large prospective studies addressing the long-term effect of TT are needed to either affects refute or corroborate these hypotheses.

INTRODUCTION:that Testosterone (T) therapy has long been considered contraindicated in men with prostate cancer (PCa). However, the traditional view regarding the clinical relationship of T to PCa has come under new scrutiny, with recent reports suggesting that PCa growth may not be ng/mL greatly affected by variations in serum T within the near-physiologic range. AIM: This report details the clinical and prostate-specific antigen of (PSA) response of a man with untreated PCa treated with T therapy for 2 years. METHODS: Measurements of serum PSA,report total and free T concentrations were obtained at regular intervals at baseline and following initiation of T therapy. MAIN OUTCOME men MEASURE: Serum PSA during T therapy. RESULTS: An 84-year-old man was seen for symptoms of hypogonadism, with serum total T the within the normal range at 400 ng/dL, but with a reduced free T of 7.4 pg/mL (radioimmunoassay [RIA], reference range voiding 10. -55. ). PSA was 8.5 ng/mL, and 8.1 ng/mL when repeated. Prostate biopsy revealed Gleason 6 cancer in both lobes. He range. refused treatment for PCa, but requested T therapy, which was initiated with T gel after informed consent regarding possible cancer and progression. Serum T increased to a mean value of 699 ng/dL and free T to 17.1 pg/mL. PSA declined to (PSA) a nadir of 5.2 ng/mL at 10 months, increased slightly to 6.2 ng/mL at 21 months, and then declined to with 3.8 ng/mL at 24 months after addition of dutasteride for voiding symptoms. No clinical PCa progression was noted. CONCLUSION: A the decline in PSA was noted in a man with untreated PCa who received T therapy for 2 years. This case changes provides support for the notion that PCa growth may not be adversely affected by changes in serum T beyond the at castrate or near-castrate range.

PURPOSE:the Pertinent literature regarding the potential use of testosterone therapy in men with prostate cancer is reviewed and synthesized. MATERIALS AND use METHODS: A literature search was performed of English language publications on testosterone administration in men with a known history of therapy prostate cancer and investigation of the effects of androgen concentrations on prostate parameters, especially prostate specific antigen. RESULTS: The prohibition of against the use of testosterone therapy in men with a history of prostate cancer is based on a model that The assumes the androgen sensitivity of prostate cancer extends throughout the range of testosterone concentrations. Although it is clear that prostate men cancer is exquisitely sensitive to changes in serum testosterone at low concentrations, there is considerable evidence that prostate cancer growth with becomes androgen indifferent at higher concentrations. The most likely mechanism for this loss of androgen sensitivity at higher testosterone concentrations testosterone is the finite capacity of the androgen receptor to bind androgen. This saturation model explains why serum testosterone appears unrelated specific to prostate cancer risk in the general population and why testosterone administration in men with metastatic prostate cancer causes rapid association progression in castrated but not hormonally intact men. Worrisome features of prostate cancer such as high Gleason score, extracapsular disease therapy and biochemical recurrence after surgery have been reported in association with low but not high testosterone. In 6 uncontrolled studies based results of testosterone therapy have been reported after radical prostatectomy, external beam radiation therapy or brachytherapy. In a total of with 111 men 2 (1.8%) biochemical recurrences were observed. Anecdotal evidence suggests that testosterone therapy does not necessarily cause increased prostate not specific antigen even in men with untreated prostate cancer. CONCLUSIONS: Although no controlled studies have been performed to date to biochemical document the safety of testosterone therapy in men with prostate cancer, the limited available evidence suggests that such treatment may cancer not pose an undue risk of prostate cancer recurrence or progression.

For strongly several decades it has been assumed that higher testosterone (T) leads to greater growth of benign and malignant prostate tissue,no but this view has come under greater scrutiny over the last several years. Although there are as yet no large-scale,and long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as risk, population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer as or exacerbation of symptoms due to benign prostatic hyperplasia. This lack of prostate risk despite increased serum T appears to assumed be explained by data showing that exogenous T does not raise intraprostatic concentrations of T or dihydrotestosterone, suggesting a saturation it model. In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more safe worrisome features of prostate cancer. In conclusion, the available evidence strongly suggests that T therapy is safe for the prostate.Although Given that the population at risk for T deficiency overlaps with the population at risk for prostate cancer, it is T strongly recommended that men undergoing T therapy undergo regular monitoring for prostate cancer.